#wet amd

1 story

#505b2 #fda #nda #ocul #ocular therapeutix #pharmaceuticals #sol-1 trial #sol-r trial

OCUL Stock Faces NDA Catalyst Test
Ocular Therapeutix's Q4 2026 NDA submission could reshape wet AMD treatment if FDA accepts its 505(b)(2) pathway.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 1m